ProCE Banner Activity

The New Array of Choices in Prostate Cancer—What’s Best for Your Patients?

Clinical Thought

A range of available and emerging therapeutic agents across the continuum of prostate cancer offer new options for healthcare providers and their patients. This commentary offers an overview of current treatment strategies and best approaches in diagnosis, treatment, and adverse event management to provide optimal outcomes for patients with prostate cancer.

Released: January 12, 2022

Expiration: January 11, 2023



Rana R. McKay

Rana R. McKay, MD

Associate Professor
Department of Medicine
Divisions of Hematology/Oncology and Urology
University of California San Diego
San Diego, California


This activity is supported by educational grants from Astellas and Bayer HealthCare Pharmaceuticals Inc.

Provided by

ProCE Banner

Target Audience

Oncology NPs, PAs, and nurses


Dr McKay: consulting fees: AstraZeneca, Bristol-Myers Squibb, Calithera, Caris, Dendreon, Exelixis, Janssen, Merck, Myovant, Novarits, Sanofi, Sorrento Therapeutics; Vividion Therapeutics; consulting fees/contracted research: Bayer, Pfizer, Tempus.

None of the members of the Planning Committee or PCE staff have any relevant relationships to disclose.


Clinical Thought


The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.

Additional Information

Program Medium

This program has been made available online.